Atara Biotherapeutics vs Fate Therapeutics
ATRA and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and FATE compare
Fate Therapeutics is the larger company, worth 1.9 times as much as Atara Biotherapeutics ($122M against $65.2M).
Fate Therapeutics grew revenue faster over the last twelve months (−23.4% versus −96.7% for Atara Biotherapeutics).
Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −269% compared with −1941% at Fate Therapeutics.
Fate Therapeutics scores higher on the StockData Score (8 against 3 for Atara Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | FATE |
|---|---|---|
| Size and price | ||
| Market cap | $65.2M | $122M |
| Share price | $6.50 | $1.02 |
| Change, 1 year | −52.8% | 5.8% |
| Change, 5 years | −98.5% | −98.1% |
| Beta (5Y) | 1.99 | 3.98 |
| Employees | 14 | 161 |
| StockData Score | ||
| Total score | 3 | 8 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.5× (better) | 18.8× |
| P/B | – | 0.8× |
| FCF yield | – | −86.4% |
| Fair value | – | $1.34 |
| Margin of safety | – | 23.8% |
| Growth | ||
| Revenue growth (TTM) | −96.7% | −23.4% (better) |
| Revenue growth, 5Y average | – | −26.7% |
| Net income growth (TTM) | −388% | – |
| Profitability | ||
| Operating margin | −230% (better) | −2058% |
| Net margin | −269% (better) | −1941% |
| FCF margin | – | −1627% |
| Return on equity | – | −60.7% |
| Return on invested capital | – | −553% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −5.0× | – |
| Current ratio | 1.98 | 4.85 (better) |
| Altman Z-score | −136.12 | −8.99 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −14.2% | – |
| Shareholder yield | −14.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 59.9% |
| Held by insiders | 55.5% | 25.7% |
| Insider net buying, 12 months | $2.0M (better) | −$336K |
| Short interest, % of float | 6.6% | 11.2% |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- FATE stock overview
- FATE income statement
- FATE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.